IMMUNOTOPE is a clinical stage biotechnology company developing  immunotherapy products for the treatment and prevention of cancer and chronic viral infections.  Our products activate the patient’s own immune system to fight disease and prevent recurrence.  Our comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the very earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Our product portfolio includes ovarian, breast and colon cancer and hepatitis.   

Immunotope's platform provides the ideal combination of technologies for successful immunotherapy.  We are developing products and services that will: 

• Address the need for highly efficacious, curative treatments with minimal toxicity
• Use the exquisite sensitivity and specificity of the immune system for early detection of cancer
• Provide innovative tools and services for collaborative development of novel drug and diagnostic products
• Provide our shareholders with exceptional returns on their investment

We use proprietary immunoproteomics technologies to identify naturally processed and presented antigens associated with Major Histocompatibility Complex Class I and Class II molecules that are present only on diseased cells. Immunotope’s lead product is the OCPM Immunotherapeutic Vaccine, a multivalent cancer therapeutic mixture of twelve different novel antigens, each of which targets a separate, critical pathway known to be present in highly aggressive tumors. An Investigational New Drug application (IND) for a Phase I clinical trial in ovarian cancer patients has been cleared by FDA, with an amendment to add a cohort of breast cancer patients under FDA review. The trial is being conducted at the Duke University Comprehensive Cancer Center.                               

Immunotope is also applying its platform technology to develop novel autoantibody-based biomarkers for early-stage detection of cancer. Performed as a simple blood test, our products will be rapid, non-invasive and indication-specific early-stage cancer diagnostics.

We are developing the theranostic uses of the subset of autoantigens that are autoantibody-reactive and  MHC-processed and presented, for combination diagnostic and therapeutic  application.